Cargando…
Musk Tongxin Dripping Pills for treating Ticagrelor in Patients After Percutaneous Coronary Intervention: Echocardiography Combined with Untargeted Metabolomics
Objectives: As current clinical practice guidelines, ticagrelor is the suggested therapeutic scheme to prevent adverse cardiovascular events in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI) treatment. However, this therapeutic strategy still fails, an...
Autores principales: | Nan, Lyu, Peng, Lai, Jinxia, Zhao, Mengzhe, Guo, Jun, Liang, Haibo, Wang, Houfa, Geng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579064/ https://www.ncbi.nlm.nih.gov/pubmed/34776957 http://dx.doi.org/10.3389/fphar.2021.731734 |
Ejemplares similares
-
Effect of Musk Tongxin Dropping Pill on Myocardial Remodeling and Microcirculation Dysfunction in Diabetic Cardiomyopathy
por: Zhao, Jingjing, et al.
Publicado: (2021) -
Shexiang Tongxin Dropping Pill Protects Against Chronic Heart Failure in Mice via Inhibiting the ERK/MAPK and TGF-β Signaling Pathways
por: Zhang, Shuying, et al.
Publicado: (2021) -
Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities
por: Zhang, Jun, et al.
Publicado: (2022) -
Shexiang Tongxin Dropping Pills Promote Macrophage Polarization-Induced Angiogenesis Against Coronary Microvascular Dysfunction via PI3K/Akt/mTORC1 Pathway
por: Lu, Xiangyu, et al.
Publicado: (2022) -
Corrigendum: Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities
por: Zhang, Jun, et al.
Publicado: (2022)